155 related articles for article (PubMed ID: 28231752)
1. Decreased HoxD10 Expression Promotes a Proliferative and Aggressive Phenotype in Prostate Cancer.
Mo RJ; Lu JM; Wan YP; Hua W; Liang YX; Zhuo YJ; Kuang QW; Liu YL; He HC; Zhong WD
Curr Mol Med; 2017; 17(1):70-78. PubMed ID: 28231752
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
4. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of PDZ-binding kinase confers malignant phenotype in prostate cancer via the regulation of E2F1.
Chen JH; Liang YX; He HC; Chen JY; Lu JM; Chen G; Lin ZY; Fu X; Ling XH; Han ZD; Jiang FN; Zhong WD
Int J Biol Macromol; 2015 Nov; 81():615-23. PubMed ID: 26314905
[TBL] [Abstract][Full Text] [Related]
6. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
7. H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.
Liu T; Chen J; Xiao S; Lei X
Tumour Biol; 2016 May; 37(5):6419-28. PubMed ID: 26631039
[TBL] [Abstract][Full Text] [Related]
8. POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in head and neck cancer.
Sharpe DJ; Orr KS; Moran M; White SJ; McQuaid S; Lappin TR; Thompson A; James JA
Oncotarget; 2014 Sep; 5(18):8803-15. PubMed ID: 25301728
[TBL] [Abstract][Full Text] [Related]
9. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
10. miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.
Xu S; Yi XM; Zhang ZY; Ge JP; Zhou WQ
Mol Med Rep; 2016 Dec; 14(6):5025-5032. PubMed ID: 27779679
[TBL] [Abstract][Full Text] [Related]
11. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer.
Chen QB; Liang YK; Zhang YQ; Jiang MY; Han ZD; Liang YX; Wan YP; Yin J; He HC; Zhong WD
Tumour Biol; 2017 Jun; 39(6):1010428317703924. PubMed ID: 28651494
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-10b promotes migration and invasion through Hoxd10 in human gastric cancer.
Wang YY; Li L; Ye ZY; Zhao ZS; Yan ZL
World J Surg Oncol; 2015 Aug; 13():259. PubMed ID: 26311318
[TBL] [Abstract][Full Text] [Related]
14. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
15. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
Guo J; Wang M; Wang Z; Liu X
PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
[TBL] [Abstract][Full Text] [Related]
17. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer.
Wang J; Cheng G; Li X; Pan Y; Qin C; Yang H; Hua L; Wang Z
Tumour Biol; 2016 Jul; 37(7):9603-13. PubMed ID: 26797783
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]